韩国的MEDIPOST与日本的Teikoku Seiyaku合作, 出售日本膝上骨髓炎的干细胞疗法CARTISTEM。 South Korea’s MEDIPOST partners with Japan’s Teikoku Seiyaku to sell its stem cell therapy CARTISTEM® for knee osteoarthritis in Japan.

韩国的MEDIPOST与日本的Teikoku Seiyaku达成了一项独家交易,将日本膝上骨髓炎的干细胞疗法CARTISTEM商业化。 South Korea’s MEDIPOST has struck an exclusive deal with Japan’s Teikoku Seiyaku to commercialize its stem cell therapy CARTISTEM® for knee osteoarthritis in Japan. Teikoku Seiyaku将处理销售、分销和促销事宜,而MEDIPOST将保留制造和供应毒品。 Teikoku Seiyaku will handle sales, distribution, and promotion, while MEDIPOST retains manufacturing and will supply the drug. MEDIPOST提前收到800万美元,这是1 000万美元的监管里程碑,今后还收到以销售为基础的付款。 MEDIPOST receives $8 million upfront, a $10 million regulatory milestone, and future sales-based payments. CARTISTEM自2012年起在韩国获得批准, 治疗了超过35 000名病人, 目的是再生软骨, Approved in South Korea since 2012, CARTISTEM® has treated over 35,000 patients and aims to regenerate cartilage, potentially modifying the disease’s progression. Teikoku计划扩大其矫形小组,并利用其医疗网络改善日本患者的就诊情况。 Teikoku plans to expand its orthopedic team and use its medical network to improve patient access in Japan.